She started her career at Novartis as study director in 1999 by establishing a GLP compliant in vitro cardiac laboratory. In 2004, she has been nominated as preclinical cardio-safety expert responsible for the global assessment of the preclinical cardio safety data and the interaction of the cardio safety group with the project team representatives. She provides expert statements to the project teams and the Integrated Safety Assessment group with regard to cardio safety issues. She is also a regular member of the safety pharmacology steering committee and, thus, contributes to the global co-ordination of the safety pharmacology activities in Novartis. In addition, she chairs the monthly cardio safety meeting, where all Novartis safety pharmacology experts and project teams meet to discuss pre-clinical cardio safety data and make recommendations to International project teams. In this function she also interacts with the clinical cardio vascular assessment group. Bérengère has also proven to be a pro-active driver of an on-going, combined experimental / computational modeling development effort in partnership with Modeling & Simulation (M&S). This highly challenging project aims at integrating cardiac signals from channel to tissue level, within a single mechanistic computer modeling platform. Bérengère provides essential experimental contributions and in-depth expert knowledge to guide and enable strategic developments of this unique modeling platform of the heart ventricle. REFERENCES:PRECLINICAL CARDIOSAFETY ASSESSMENT OF TORSADOGENIC RISK AND ALTERNATIVE METHODS TO ANIMAL EXPERIMENTATION: THE INSEPARABLE TWINS. BERENGERE M DUMOTIER and ANNA V GEORGIEVA. Cell Biology and Toxicology; in press. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Bottino D, Penland RC, stamps A, Traebert M, Dumotier B, Georgiva A, Helmlinger G, Lett GS. Prog Biophys Mol Biol. 2006 Jan-Apr;90(1-3):414-43. Antimalarial drugs: QT prolongation and cardiac arrhythmias. Traebert M, Dumotier B. Expert Opin Drug Saf. 2005 May;4(3):421-31. Review.Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W. Eur J Pharmacol. 2004 Jan 19;484(1):41-8. "Use-dependent" effects of cisapride on postrest action potentials in rabbit ventricular myocardium. Dumotier BM, Bastide M, Adamantidis MM. Eur J Pharmacol. 2001 Jun 22;422(1-3):137-48. Chronic amiodarone effects on epicardial conduction and repolarization in the isolated porcine heart. Lacroix D, Sautiere K, Adamantidis M, Dumotier B, Grandmougin D, Extramiana F, Kacet S, Dupuis B. Pacing Clin Electrophysiol. 2000 Jul;23(7):1133-43. Electrophysiologic effects and arrhythmogenic potential of diphemanil methylsulfate on rabbit purkinje fibers. Correlations with clinical observations of QT prolongation in pediatrics. Adamantidis M, Dumotier B, Caron J, Dupuis B. Arch Mal Coeur Vaiss. 1998 Dec;91(12):1487-94. French.Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Adamantidis MM, Dumotier BM, Caron JF, Bordet R. Fundam Clin Pharmacol. 1998;12(1):70-6. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA. Br J Pharmacol. 1996 Apr;117(7):1377-9.
Personal Web Links
Forward
Print
10 online sources [ view sources ]
American Society for Pharmacology and Experimental Therapeutics
